<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03056274</url>
  </required_header>
  <id_info>
    <org_study_id>RVR</org_study_id>
    <nct_id>NCT03056274</nct_id>
  </id_info>
  <brief_title>Metformin in Intrahepatic Cholestasis of Pregnancy</brief_title>
  <acronym>METRIC</acronym>
  <official_title>METformin in Intrahepatic Cholestasis of Pregnancy (METRIC) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epsom and St Helier University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College Hospital NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medway NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Epsom and St Helier University Hospitals NHS Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study aimed at comparing the effect of metformin versus ursodeoxycholic acid
      in women with intrahepatic cholestasis in pregnancy. The study will be conducted in three NHS
      hospital sites, over an 18 month period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intrahepatic cholestasis is a condition that affects pregnant women. It is characterised by
      itching, usually in the third trimester of pregnancy and is associated with an increase in
      the liver enzymes and bile salts. This can be associated with maternal and neonatal
      morbidity, and rarely perinatal mortality.

      The investigators propose to assess and compare the effect of Metformin versus
      Ursodeoxycholic acid on lowering liver enzymes and bile salts, improving maternal morbidity
      and improving neonatal outcomes.

      This study is a pilot study that will be conducted at 3 NHS hospital sites where patients
      will randomly assigned to receive either Metformin or Ursodeoxycholic acid. There will be 20
      patient in each arm. Recruitment will commence in February 2017 and will run for an 18 month
      period.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normalisation of maternal serum concentration of bile salts and liver enzymes</measure>
    <time_frame>From date of randomisation to date of delivery assessed up to 26 weeks</time_frame>
    <description>Normalisation of Bile acids and liver enzymes - both parameters are the cornerstone for a diagnosis of intrahepatic cholestasis. They have been separated into two outcomes due to to the different laboratory indices of measurement. Results will be aggregated together to report number of patients with abnormal results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Normalisation of maternal serum concentration of liver enzymes</measure>
    <time_frame>From date of randomisation to date of delivery assessed up to 26 weeks</time_frame>
    <description>Normalisation of liver enzymes Alanine transaminase Aspartate transaminase Bilirubin (total) Gamma glutamyl transferase Results will be aggregated together to report the number of patients with abnormal liver enzymes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fetal outcomes</measure>
    <time_frame>From date of randomisation to date of delivery assessed up to 26 weeks</time_frame>
    <description>Perinatal death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal outcomes</measure>
    <time_frame>From date of randomisation to date of delivery assessed up to 26 weeks</time_frame>
    <description>Preterm delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal outcomes</measure>
    <time_frame>Immediately upon delivery date</time_frame>
    <description>Respiratory distress syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal outcomes</measure>
    <time_frame>Immediately upon delivery date</time_frame>
    <description>Birth weight (g)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal outcomes</measure>
    <time_frame>Immediately upon delivery date</time_frame>
    <description>Birth weight percentile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal outcomes</measure>
    <time_frame>Immediately upon delivery date</time_frame>
    <description>Gestational age at delivery</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Fetal outcomes</measure>
    <time_frame>Immediately upon delivery date</time_frame>
    <description>Presence of meconium</description>
  </other_outcome>
  <other_outcome>
    <measure>Fetal outcomes</measure>
    <time_frame>Immediately upon delivery date</time_frame>
    <description>APGAR score at 5 minutes</description>
  </other_outcome>
  <other_outcome>
    <measure>Fetal outcomes</measure>
    <time_frame>Immediately upon delivery date</time_frame>
    <description>Umbilical arterial pH at birth</description>
  </other_outcome>
  <other_outcome>
    <measure>Maternal outcomes</measure>
    <time_frame>From date of randomisation to date of delivery assessed up to 26 weeks</time_frame>
    <description>Symptoms (itch) - assessed by questionnaire at clinic visits</description>
  </other_outcome>
  <other_outcome>
    <measure>Maternal outcomes</measure>
    <time_frame>From date of randomisation to date of delivery assessed up to 20 weeks</time_frame>
    <description>Maximum dose of medication required</description>
  </other_outcome>
  <other_outcome>
    <measure>Maternal outcomes</measure>
    <time_frame>From date of randomisation to date of delivery assessed up to 20 weeks</time_frame>
    <description>Gestational diabetes</description>
  </other_outcome>
  <other_outcome>
    <measure>Maternal outcomes</measure>
    <time_frame>From date of randomisation to date of delivery assessed up to 26 weeks</time_frame>
    <description>Postpartum haemorrhage</description>
  </other_outcome>
  <other_outcome>
    <measure>Maternal outcomes</measure>
    <time_frame>From date of randomisation to date of delivery assessed up to 20 weeks</time_frame>
    <description>Mode of delivery</description>
  </other_outcome>
  <other_outcome>
    <measure>Maternal outcomes</measure>
    <time_frame>From date of randomisation to date of delivery assessed up to 26 weeks</time_frame>
    <description>Liver failure</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Intrahepatic Cholestases</condition>
  <condition>Pregnancy Complications</condition>
  <arm_group>
    <arm_group_label>Metformin arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ursodeoxycholic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ursodeoxycholic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin Hydrochloride (HCl) Tablets, is an oral antihyperglycemic drug used in the management of type 2 diabetes</description>
    <arm_group_label>Ursodeoxycholic acid</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodeoxycholic Acid</intervention_name>
    <description>Ursodeoxycholic acid (UDCA) is used to treat gallstones and primary biliary cirrhosis. UDCA is also used to treat obstetric cholestasis (OC), a liver condition that occurs specifically in pregnancy.</description>
    <arm_group_label>Metformin arm</arm_group_label>
    <other_name>Destolit速, Urdox速, Ursofalk速, Ursogal速</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 20+0 to 40 weeks' gestation on day of randomisation

          2. Itching with a raised serum bile acid above the upper limit of normal

          3. Normal anomaly scan at 20 weeks

          4. Aged 18 years or over

          5. Able to give written informed consent

          6. No known pre-existing liver disease

        Exclusion Criteria:

          1. Decision already made for delivery within the next 48 hours

          2. Known allergy to any component of the ursodeoxycholic acid or metformin tablets

          3. Patients already on metformin for other conditions
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hassan Shehata, FRCPI, FRCOG</last_name>
    <role>Principal Investigator</role>
    <affiliation>Epsom &amp; St Helier University Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hassan Shehata, FRCPI, FRCOG</last_name>
    <phone>01372 735735</phone>
    <phone_ext>6887</phone_ext>
    <email>hassan.shehata@esth.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amanda Ali, MRCPI, MRCOG</last_name>
    <email>amandaha.ali@gmail.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Elfituri A, Ali A, Shehata H. Managing Recurring Obstetric Cholestasis With Metformin. Obstet Gynecol. 2016 Dec;128(6):1320-1323.</citation>
    <PMID>27824743</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2016</study_first_submitted>
  <study_first_submitted_qc>February 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2017</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metformin</keyword>
  <keyword>Ursodeoxycholic acid</keyword>
  <keyword>Outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Pregnancy Complications</mesh_term>
    <mesh_term>Cholestasis, Intrahepatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

